Arvinas Inc is a pioneering biotech firm focused on developing innovative treatments by targeting disease-causing proteins for degradation. Utilizing its proprietary PROTAC technology, Arvinas is advancing a novel class of therapies, including potential treatments for prostate cancer and breast cancer. With ongoing clinical trials and strategic partnerships with major pharmaceutical companies, Arvinas is at the forefront of leveraging the body's natural processes to fight serious diseases. Founded in 2013, the company is headquartered in New Haven, Connecticut, marking a significant player in the biotechnology industry.

ARVN Articles